Portal de Periódicos da CAPES

Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients

2020; Elsevier BV; Volume: 83; Issue: 1 Linguagem: Inglês

10.1016/j.jaad.2020.01.066

1097-6787

Shannon Humphrey, Derek Jones, Jean Carruthers, Alastair Carruthers, Katie Beleznay, Naissan O. Wesley, Jeanette M. Black, Sherri Vanderveen, Ardalan Minokadeh,

Dermatologic Treatments and Research

Background Recent publications have suggested an increased risk of delayed adverse events (DAEs) with a smooth, cohesive 20-mg/mL hyaluronic acid filler, Juvéderm Voluma (HA-V). Objective To examine the occurrence of HA-V DAEs and identify patterns and characteristics. Methods Charts from patients who received HA-V between February 1, 2009, and February 28, 2018 from 2 clinics were analyzed. Results In 4500 patients who received 9324 treatments with HA-V, 44 DAEs were identified, for a combined incidence of 0.98% per patient, 0.47% per treatment, and 0.23% per syringe. Patients with DAEs received a slightly larger cumulative amount of HA-V than those who did not. Delayed swelling and nodule formation were the most common reactions and occurred a median of 4 months after treatment, with an increase in frequency between October and January. About a third were preceded by an identifiable immunologic stimulus. DAEs were transient and resolved without incident. Limitations The retrospective nature made it difficult to capture time to resolution or remember potential triggers. Conclusion In this large, long-term, retrospective review, HA-V DAEs occurred at a rate of 0.98% per patient. Although the exact cause has yet to be elucidated, we hypothesize that an increase in fragmentation during the HA-V degradation process may trigger an inflammatory response after an immunologic trigger. Recent publications have suggested an increased risk of delayed adverse events (DAEs) with a smooth, cohesive 20-mg/mL hyaluronic acid filler, Juvéderm Voluma (HA-V). To examine the occurrence of HA-V DAEs and identify patterns and characteristics. Charts from patients who received HA-V between February 1, 2009, and February 28, 2018 from 2 clinics were analyzed. In 4500 patients who received 9324 treatments with HA-V, 44 DAEs were identified, for a combined incidence of 0.98% per patient, 0.47% per treatment, and 0.23% per syringe. Patients with DAEs received a slightly larger cumulative amount of HA-V than those who did not. Delayed swelling and nodule formation were the most common reactions and occurred a median of 4 months after treatment, with an increase in frequency between October and January. About a third were preceded by an identifiable immunologic stimulus. DAEs were transient and resolved without incident. The retrospective nature made it difficult to capture time to resolution or remember potential triggers. In this large, long-term, retrospective review, HA-V DAEs occurred at a rate of 0.98% per patient. Although the exact cause has yet to be elucidated, we hypothesize that an increase in fragmentation during the HA-V degradation process may trigger an inflammatory response after an immunologic trigger.